⌘K

08:33:00·100d

PRReleasevia Quantisnow

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

ByQuantisnow·Wall Street's wire, on your screen.

SRPT· Sarepta Therapeutics Inc.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Director Boor Kathryn Jean was granted 16,875 shares, increasing direct ownership by 204% to 25,138 units (SEC Form 4)
Director Mayo Stephen was granted 16,875 shares, increasing direct ownership by 956% to 18,640 units (SEC Form 4)
Director Wigzell Hans Lennart Rudolf was granted 16,875 shares, increasing direct ownership by 67% to 42,098 units (SEC Form 4)
Director Behrens M Kathleen was granted 16,875 shares, increasing direct ownership by 9% to 214,357 units (SEC Form 4)
Director Connelly Deirdre P was granted 16,875 shares, increasing direct ownership by 323% to 22,100 units (SEC Form 4)